Index · Artikel · In challenge to personalized cancer care, DNA isn't all-powerful

In challenge to personalized cancer care, DNA isn't all-powerful

2012-12-14 2
   
Advertisement
résuméNEW YORK The cancer cells were not behaving the way the textbooks say they should. Some of the cells in colonies that were started with colorectal tumor cells were propagating like mad; others were hardly multiplying. Some were dropping dead from che
Advertisement

In challenge to personalized cancer care, DNA isn't all-powerful


NEW YORK The cancer cells were not behaving the way the textbooks say they should. Some of the cells in colonies that were started with colorectal tumor cells were propagating like mad; others were hardly multiplying. Some were dropping dead from chemotherapy and others were no more slowed by the drug than is a tsunami by a tissue. Yet the cells in each "clone" all had identical genomes, supposedly the all-powerful determinant of how cancer cells behave.

That finding, published online Thursday in Science, could explain why almost none of the new generation of "personalized" cancer drugs is a true cure, and suggests that drugs based on genetics alone will never achieve that holy grail.

Scientists not involved in the study praised it for correcting what Dr. Charis Eng, an oncologist and geneticist who leads the Genomic Medicine Institute at the Cleveland Clinic, called "the simple-minded" idea that tumor genomes alone explain cancer.

Calling the study "very exciting," she said the finding underlines that a tumor's behavior and, most important, its Achilles heel depend on something other than its DNA. Her own work, for instance, has shown that patients with identical mutations can have different cancers.

The core premise of the leading model of cancer therapy is that cells become malignant when they develop mutations that make them proliferate uncontrolled. Find a molecule that targets the "driver" mutation, and a pharmaceutical company will have a winner and patients will be cancer-free.

That's the basis for "molecularly targeted" drugs such as Pfizer's Xalkori for some lung cancers and Novartis's Gleevec for chronic myeloid leukemia. When those drugs stop working, the dogma says, it is because cells have developed new cancer-causing mutations that the drugs don't target.

In the new study, however, scientists found that despite having identical genetic mutations, colorectal cancer cells behaved as differently as if they were genetic strangers. The findings challenge the prevailing view that genes determine how individual cells in a solid tumor behave, including how they respond to chemotherapy and how actively they propagate.

If DNA is not the sole driver of tumors' behavior, said molecular geneticist John Dick of the Princess Margaret Cancer Centre in Toronto, who led the study, it suggests that, to vanquish a cancer entirely, drugs will have to target their non-genetic traits too, something few drug-discovery teams are doing.

Genomes are what cutting-edge clinics test for when they try to match a patient's tumor to the therapy most likely to squelch it.

For their study, Antonija Kreso, Catherine O'Brien and other scientists under Dick's direction took colorectal cancer cells from 10 patients and transplanted them into mice. They infected the cells with a special virus that let them track each cell, even after it divided and multiplied and was transplanted into another mouse, then another and another, through as many as five such "passages."

Only one in 10,000 tumor cells was responsible for keeping the cancer growing, the scientists found - in some cases for 500 days of repeated transplantation from one mouse to the next. Genetically-identical tumor cells stopped dividing within 100 days even without treatment.

Tumor cells that were not killed by chemotherapy - the scientists used oxaliplatin, a colon-cancer drug sold by Sanofi as Eloxatin - had the same mutations as cells that were. The survivors tended to be dormant, non-proliferating ones that suddenly became activated, causing the tumor to grow again. Yet the cells - dormant or active, invulnerable to chemo or susceptible - had identical genomes.

"I thought we'd be able to look at the genetics that let some cells propagate, or not be susceptible to chemotherapy, but lo and behold there was no genetic difference," said Dick. "That goes against a main dogma of the cancer enterprise: that if a tumor comes back after treatment it's because some cells acquired mutations that made them resistant."

That's true in some cases, he said, "but what our data are saying is, there are other biological properties that matter. Gene sequencing of tumors is definitely not the whole story when it comes to identifying which therapies will work."

The results were surprising enough, Dick said, that experts reviewing the paper for Science asked him to run additional tests to make sure the cells that behaved so differently were in fact genetic twins. He did, they were, and Science accepted the paper.

Other experts also praised the work, saying it supported the growing suspicion in the field that personalized cancer therapy is oversimplistic, at least in how it's sold to the public.

"It's not as simple as just sequencing mutations to tailor therapies to each tumor," said surgical oncologist Dr. Steven Libutti of the Montefiore Einstein Center for Cancer Care in New York City. "In my mind, the findings are not unexpected. Other things besides genes matter: the environment in which a tumor is growing, for instance, plays an important role in whether therapy will be effective."

Rather than targeting DNA alone, the Toronto scientists suspect, effective therapies would also take aim at what phase of its cycle a cell is in (dormant, growing or dividing, for example), which of its genes are activated, whether it sits in a region of the tumor that is starved of oxygen, and other non-genetic properties.

Nudging tumor cells out of their dormant phase and into their growth cycles, for instance, could make them more susceptible to chemotherapy, which generally targets rapidly dividing cells.

"Our findings raise questions about the resources put into sequence, sequence, sequence," said Dick. "That has led to one kind of therapeutic" - molecularly-targeted drugs - "but not the cures the public is being promised."

(Reporting by Sharon Begley; editing by Claudia Parsons)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated

  • Muss ich bis sieben Tage warten, bevor mein neues pac starten?

    Ich habe drei Wochen im Wert von Pillen, nachdem die letzte Pille, die ich mit der nächsten Packung beginnen Sie oder sieben Tage warten ----schneiden---- In Antwort auf die Marvell bei 2009-08-24 05.29 Ich bin mir nicht sicher, warum Sie drei Wochen
  • Der Mythos von Green Rindfleisch

    Der Mythos von Green Rindfleisch
    Dumme Jilly / flickr Wenn ich einen Lebensmittel zu nennen, die auf dem heißen Stuhl in den letzten 30 Jahren gewesen ist, wäre es Rindfleisch sein. Steht im Zusammenhang mit Herz-Kreislauf-Erkrankungen und verleumdet für seine Industrie Abhängigkeit
  • Wenn ich eine kalte Wunde für ein paar Tage hatte ich noch Abreva benutzen?

    Leider habe ich am Montagnachmittag eine kalte Wunde auf der linken oberen Ecke meines lip.I auch eine Gruppe von roten Blasen an der Innenseite des gleichen region.I bemerkt bemerkt begann am dritten Tag Abreva Verwendung ohne Ergebnis yet.In hinaus
  • Kann Ursache unregelmäßige Perioden Amitriptylin?

    iv hatte iregular Blutung hatte Test für dieses Problem getan kam alles wieder in Ordnung, könnte es sich um eine Nebenwirkung von Amitriptylin für mehr als 2 Jahre auf Amitriptylin auf ihnen da sein Biene ----schneiden---- In der Antwort auf Rajive
  • Wie es oder nicht, ist Ruf Schlüssel zu Amerikas besten Krankenhäuser

    Wie es oder nicht, ist Ruf Schlüssel zu Amerikas besten Krankenhäuser
    Liebe 'em oder Hass' em, US News & World Report Krankenhaus - Rankings haben sich in den letzten zwei Jahrzehnten ein Goldstandard geworden , durch die Verbraucher im Gesundheitswesen Entscheidungen zu treffen. Aber in einer Annals of Internal Medici
  • Brown Entlader? Auf Geburtenkontrolle (Tri-Sprintec). Was geht?

    Ok, das ist mein 8. Monat auf Geburtenkontrolle sein. Ich habe noch nie irgendwelche Nebenwirkungen (einschließlich Spek zwischen den Perioden) hatte, die ich mich erinnern kann. Wie auch immer, ich wurde sexuell aktiv im letzten Monat (wir immer Kon
  • Was bei Ihrem Kind die In-Home Ergotherapie Auswertung zu erwarten

    Was bei Ihrem Kind die In-Home Ergotherapie Auswertung zu erwarten
    Sie haben Ihre Sorgen um Ihr Baby oder Kleinkind Entwicklung zu seinem oder ihrem Kinderarzt mitgeteilt, haben Sie mit Ihrem lokalen frühen Interventionsstelle verbunden, um eine Entwicklungs Auswertung einzurichten, und Sie haben sich für die kommen
  • Tax Day Linked in Fatal Car Crashes zu erhöhen

    Tax Day Linked in Fatal Car Crashes zu erhöhen
    Bildnachweis: Dreamstime Der Stress der Einreichung Steuern leicht die Zahl der tödlichen Autounfälle in den Vereinigten Staaten erhöhen kann, schlägt eine neue Studie. Im Durchschnitt wurden 226 Menschen in tödliche Autounfälle auf steuerliche Tag b
  • Mirena - Ist das normal nach dem Einsetzen?

    Ich hatte mirena in Montag gesetzt, und ich hatte wirklich böse Entlastung wie die Dr sagte mir, ich würde. Ich ging nur eine große Gerinnsel über die Größe von 3/4. ----schneiden---- In Antwort auf Le Ella ... bei 2012.12.28 19.56 Die mirena ist seh
  • Die Behandlung von hormonellen Akne bei Frauen

    Die Behandlung von hormonellen Akne bei Frauen
    Damen, Erwachsenen Akne ist ein häufiges Problem. Es kann auch schwierig sein, zu behandeln. Diese Akne wäscht und astringents Sie als Teenager verwendet wird wahrscheinlich nicht für die Art der Ausbrüche arbeiten Sie jetzt mit sind. Das ist, weil e